TABLE 3.
Efficacy of live KBNP-C4152R2L vaccine against a different genotype (III) virus, KJW
| Group | Vaccine titer (EID50) | Test virus | HI titer at 21 DPI (log2) | Survival ratea |
|---|---|---|---|---|
| Control | 0 | La Sota | 0 | 0/13 (0) |
| KBNP-C4152R2L | 0 | |||
| KBNP-C4152R2L | 105 | La Sota | 4.6 ± 0.9 | 11/11 (100) |
| KBNP-C4152R2L | 5.3 ± 0.5 | |||
| 106 | La Sota | 5.3 ± 1.1 | 12/12 (100) | |
| KBNP-C4152R2L | 5.7 ± 0.6 | |||
| 107 | La Sota | 4.7 ± 1.3 | 13/13 (100) | |
| KBNP-C4152R2L | 5.2 ± 0.7 | |||
| 108 | La Sota | 5.1 ± 1.2 | 13/13 (100) | |
| KBNP-C4152R2L | 5.3 ± 1.0 | |||
| Avinew | 1 dose | La Sota | 7.3 ± 1.2 | 12/12 (100) |
| KBNP-C4152R2L | 6.2 ± 1.3 |
a
Survival rate after challenge with KJW (2 × 105 TCID50/chicken on DPI 22 via the intranasal route), shown as number surviving/total number challenged (percent).